unknown
Stage
About
EvolveImmune develops trispecific T cell engager therapies with integrated CD2 costimulation to address resistance in cancer immunotherapy, advancing a lead candidate EVOLVE104 into clinical trials.
Explore EvolveImmune's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.